2. Search Result
Search Result
Results for "

hypoxic tumors

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

2

Screening Libraries

2

Peptides

9

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6782
    Oligomycin
    Maximum Cited Publications
    105 Publications Verification

    		 Oxidative Phosphorylation ATP Synthase Fungal Antibiotic Infection Cancer
    Oligomycin, an antifungal antibiotic, is an inhibitor of H +-ATP-synthase. Oligomycin blocks oxidative phosphorylation and the electron transport chain. Oligomycin inhibits HIF-1alpha expression in hypoxic tumor cells .
    Oligomycin
  • HY-B1247
    Protoporphyrin IX
    20+ Cited Publications

    PPIX

    		 Endogenous Metabolite Others
    Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX
  • HY-105129
    Pimonidazole hydrochloride
    5+ Cited Publications

    		 Biochemical Assay Reagents Cancer
    Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
    Pimonidazole hydrochloride
  • HY-105129A
    Pimonidazole
    5+ Cited Publications

    		 Biochemical Assay Reagents Cancer
    Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
    Pimonidazole
  • HY-13767
    Tirapazamine
    10+ Cited Publications

    SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone

    		 DNA/RNA Synthesis Cancer
    Tirapazamine (SR259075) is an anticancer agent that shows selective cytotoxicity for hypoxic cells in solid tumors, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. Tirapazamine is an anticancer and bioreductive agent.Tirapazamine (SR259075) can enhance the cytotoxic effects of ionizing radiation in hypoxic cells .
    Tirapazamine
  • HY-124379
    TPCK
    1 Publications Verification

    L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK

    		 Ser/Thr Protease HPV Apoptosis PDK-1 Infection Neurological Disease Inflammation/Immunology Cancer
    TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the PDK1/Akt pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats .
    TPCK
  • HY-119264
    PRLX-93936

    		Molecular Glues Ras Apoptosis HIF/HIF Prolyl-Hydroxylase Cancer
    PRLX-93936 is a molecular Glues that binds to and reprograms the TRIM21 ubiquitin ligase to degrade nuclear pore complexes. PRLX-93936 binds to TRIM21, forms a ternary complex with TRIM21 and NUP98, and mediates the ubiquitination and proteasomal degradation of NUP98 and other nuclear pore complex proteins. PRLX-93936 induces the loss of short-lived cytoplasmic mRNA transcripts, triggers cancer cell apoptosis (Apoptosis), and inhibits the activated Ras pathway. PRLX-93936 inhibits HIF-1 under hypoxic conditions (IC50 = 0.09 μM in cell-based reporter gene assay). PRLX-93936 suppresses tumor growth in mouse models and improves survival rates in mouse models of multiple myeloma. PRLX-93936 is applicable to research related to pancreatic cancer and multiple myeloma .
    PRLX-93936
  • HY-W016409
    Ethyl 3,4-dihydroxybenzoate
    1 Publications Verification

    Protocatechuic acid ethyl ester

    		 HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis Metabolic Disease Cancer
    Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
    Ethyl 3,4-dihydroxybenzoate
  • HY-40136
    cis-4-Hydroxy-L-proline

    		Endogenous Metabolite Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
    cis-4-Hydroxy-L-proline
  • HY-119264A
    PRLX-93936 dihydrochloride

    		Molecular Glues Apoptosis Ras HIF/HIF Prolyl-Hydroxylase Cancer
    PRLX-93936 dihydrochloride is a molecular Glues that binds to and reprograms the TRIM21 ubiquitin ligase to degrade nuclear pore complexes. PRLX-93936 dihydrochloride binds to TRIM21, forms a ternary complex with TRIM21 and NUP98, and mediates the ubiquitination and proteasomal degradation of NUP98 and other nuclear pore complex proteins. PRLX-93936 dihydrochloride induces the loss of short-lived cytoplasmic mRNA transcripts, triggers cancer cell apoptosis (Apoptosis), and inhibits the activated Ras pathway. PRLX-93936 dihydrochloride inhibits HIF-1 under hypoxic conditions (IC50 = 0.09 μM in cell-based reporter gene assay). PRLX-93936 dihydrochloride suppresses tumor growth in mouse models and improves survival rates in mouse models of multiple myeloma. PRLX-93936 dihydrochloride is applicable to research related to pancreatic cancer and multiple myeloma .
    PRLX-93936 dihydrochloride
  • HY-P1435
    NoxA1ds

    		NADPH Oxidase Cardiovascular Disease Cancer
    NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds inhibits NOX1-derived O 2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .
    NoxA1ds
  • HY-B1247R
    Protoporphyrin IX (Standard)

    PPIX (Standard)

    		 Reference Standards Endogenous Metabolite Others
    Protoporphyrin IX (Standard) is the analytical standard of Protoporphyrin IX. This product is intended for research and analytical applications. Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX (Standard)
  • HY-N13009
    MO-2097

    		Raf HIF/HIF Prolyl-Hydroxylase ERK MEK Reactive Oxygen Species (ROS) Apoptosis Caspase Cancer
    MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the RAF/MEK/ERK signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer .
    MO-2097
  • HY-13730
    Porfiromycin

    N-Methylmitomycin C; NSC-56410; U-14743

    		 DNA Alkylator/Crosslinker Cancer
    Porfiromycin (N-Methylmitomycin C) is a bioreductive alkylating agent that preferentially kill hypoxic tumor cells relative to other aerobic counterparts .
    Porfiromycin
  • HY-D1450
    IR-1048

    S01448

    		 Fluorescent Dye Cancer
    IR-1048 is a nitroreductase (NTR)-responsive near-infrared fluorescence (NIR)/photoacoustic (PA) imaging probe and photothermal agent. IR-1048 is coupled with a nitroimidazole group to form IR-1048-MZ. IR-1048-MZ is catalytically reduced by NTR in a hypoxic environment, restoring strong near-infrared absorption and fluorescence emission (NIR II window), while activating the photothermal effect. IR-1048 relies on NTR-mediated electron transfer to relieve intramolecular fluorescence quenching, achieving specific imaging and photothermal ablation of tumor hypoxic areas. IR-1048 is mainly used for high-contrast NIR II/photoacoustic imaging and photothermal therapy research and tumor diagnosis of the tumor hypoxic microenvironment .
    IR-1048
  • HY-170779
    DOTA-NI-FAPI-04

    		FAP Cancer
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .
    DOTA-NI-FAPI-04
  • HY-B1247A
    Protoporphyrin IX disodium
    20+ Cited Publications

    PPIX disodium

    		 Endogenous Metabolite Cancer
    Protoporphyrin IX disodium is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX disodium also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX disodium is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX disodium causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX disodium is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Protoporphyrin IX disodium
  • HY-40136S
    cis-4-Hydroxy-L-proline-d3

    		Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    cis-4-Hydroxy-L-proline-d3 is the deuterium labeled cis-4-Hydroxy-L-proline (HY-40136). cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
    cis-4-Hydroxy-L-proline-d3
  • HY-105061
    Misonidazole

    Ro 7-0582; SR 1354

    		 Bacterial Parasite Infection Cancer
    Misonidazole (Ro 7-0582; SR 1354) is a hypoxic tumor cell radiosensitizer . Misonidazole also has antimicrobial effects .
    Misonidazole
  • HY-105211
    KU-2285

    		Biochemical Assay Reagents Cancer
    KU-2285 is an orally active fluorinated 2-nitroimidazole hypoxic cell radiosensitizer. KU-2285 has higher lipophilicity, superior sensitizing activity to Etanidazole (HY-116972), and lower neurotoxicity. KU-2285 can be used in research related to tumor diagnosis .
    KU-2285
  • HY-169100
    Antiproliferative agent-57

    		VEGFR PI3K Akt mTOR p38 MAPK HIF/HIF Prolyl-Hydroxylase Cancer
    Antiproliferative agent-57 (compound M2) is a tumor angiogenesis inhibitor. Antiproliferative agent-57 inhibits the secretion of VEGF in SiHa cells under hypoxic conditions (IC50=0.68 μM) without inducing cytotoxicity. Antiproliferative agent-57 can modulate the PI3K/AKT/mTOR and MAPK signaling pathways in tumor cells to inhibit the expression of HIF-1α and VEGF in tumor tissues .
    Antiproliferative agent-57
  • HY-155003
    TPEQM-DMA

    		Fluorescent Dye Cancer
    TPEQM-DMA is a NIR-II photosensitizer. TPEQM-DMA accumulates in cancerous mitochondria, and inhibits cancer cell growth. TPEQM-DMA has potent type-I phototherapeutic efficacy to overcome the intrinsic pitfalls of PDT in combating hypoxic tumors .
    TPEQM-DMA
  • HY-118722
    RB-90740

    		DNA/RNA Synthesis Cytochrome P450 Cancer
    RB-90740 is a type of biological reducing agent. RB-90740 is activated through metabolic reduction and generates cytotoxic products, thereby selectively killing tumor cells (usually in a hypoxic environment). RB-90740 has selective toxicity towards hypoxic cells, which is mainly achieved by causing DNA strand breaks and activating reducing enzymes (such as Cytochrome P450). RB-90740 does not initially exhibit cytotoxicity similar to its in vitro properties in hypoxic cells in mouse models. RB-90740 can be used to study the tumor physiological environment
    RB-90740
  • HY-117249
    Sanazole

    AK-2123

    		 Apoptosis Caspase Cancer
    Sanazole (AK-2123) is a hypoxic cell radiosensitizer. Sanazole enhances radiation-induced DNA strand breaks. In mouse fibroblast tumors, Sanazole increases nuclear condensation and fragmentation, as well as elevates caspase-3 activity, thereby enhancing radiation-induced apoptosis .
    Sanazole
  • HY-156169
    hCAIX/XII-IN-7

    		Carbonic Anhydrase Cancer
    hCAIX/XII-IN-7 (compound 3e) is a potent hCA IX and XII inhibitor with Kis of 3.2 nM, 9.2 nM, 503.7 nM and 59 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. hCAIX/XII-IN-7 has the potential for hypoxic tumors research .
    hCAIX/XII-IN-7
  • HY-W272058
    Isometronidazole

    		Drug Derivative Cancer
    Isometronidazole is a hypoxic cell sensitizer. Isometronidazole (750 mg/kg) shows an efficacy as a hypoxic cell sensitizer in severely hypoxic FaDu tumors but not in less hypoxic GL tumors.
    Isometronidazole
  • HY-W272058R
    Isometronidazole (Standard)

    		Biochemical Assay Reagents Reference Standards Cancer
    Isometronidazole (Standard) is the analytical standard of Isometronidazole. This product is intended for research and analytical applications. Isometronidazole is a hypoxic cell sensitizer. Isometronidazole (750 mg/kg) shows an efficacy as a hypoxic cell sensitizer in severely hypoxic FaDu tumors but not in less hypoxic GL tumors.
    Isometronidazole (Standard)
  • HY-170565
    CHD-1

    		Mitophagy Apoptosis Cancer
    CHD-1 is a a hypoxia-activated antitumor prodrug. CHD-1 impairs mitochondrial morphology and membrane potential in hypoxic tumor cells, further triggering excessive mitophagy and inducing apoptosis. CHD-1 inhibits the growth of hypoxic tumor cells in vitro and the growth of HeLa xenograft in vivo .
    CHD-1
  • HY-159132
    CAIX/CAXII-IN-2

    		Carbonic Anhydrase Cancer
    CAIX/CAXII-IN-2 (compound 23) is a CAIX/CAXII inhibitor, with Ki values ​​of 8.9 nM and 5.3 nM for CAIX/CAXII, respectively. CAIX/CAXII-IN-2 can be used in cancer research .
    CAIX/CAXII-IN-2
  • HY-U00279B
    Nitracrine hydrochloride

    		DNA/RNA Synthesis Cancer
    Nitracrine hydrochloride is a platinum-based antineoplastic drug with selective toxicity to hypoxic cells. Nitracrine hydrochloride exhibits significant cytotoxicity against the Chinese hamster ovary cell line AA8 under hypoxic conditions. Nitracrine hydrochloride exerts its effect by binding to the insertion of DNA and forming covalent adducts. The cytotoxicity of Nitracrine hydrochloride under hypoxic conditions is related to its reductive metabolism to form alkylated substances. At the same time, it may enhance the reactivity to DNA through the insertion of DNA, thereby improving the efficacy. Nitracrine hydrochloride can also inhibit RNA synthesis, contributing to its anti-tumor effect .
    Nitracrine hydrochloride
  • HY-105129AS
    Pimonidazole-d10

    		Isotope-Labeled Compounds Cancer
    Pimonidazole-d10 is the deuterium labeled Pimonidazole. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
    Pimonidazole-d10
  • HY-105129R
    Pimonidazole hydrochloride (Standard)

    		Reference Standards Others Cancer
    Pimonidazole (hydrochloride) (Standard) is the analytical standard of Pimonidazole (hydrochloride). This product is intended for research and analytical applications. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
    Pimonidazole hydrochloride (Standard)
  • HY-105129AR
    Pimonidazole (Standard)

    		Reference Standards Others Cancer
    Pimonidazole (Standard) is the analytical standard of Pimonidazole. This product is intended for research and analytical applications. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
    Pimonidazole (Standard)
  • HY-163545
    Tc-Me2P

    		Drug Derivative Cancer
    Tc-Me2P is a 99MTC-labeled acrylamide (PnAO) derivative that contains two 4-methyl-2-nitroimidazole groups. The primary activity of Tc-Me2P is as an imaging agent for tumor hypoxia. By specifically binding to hypoxic regions in tumor tissue, it can be used for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging to detect hypoxia in tumors. Tc-Me2P can be used to study the targeting of different chemical structures in tumors and normal tissues .
    Tc-Me2P
  • HY-149257
    HAT-SIL-TG-1&AT

    		JAK STAT Cancer
    HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions .
    HAT-SIL-TG-1&AT
  • HY-175638
    Carbonic anhydrase-IN-35

    		Carbonic Anhydrase Apoptosis Bcl-2 Family CDK Cancer
    Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (Ki = 0.6 nM) and hCA XII (Ki = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC50 = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer .
    Carbonic anhydrase-IN-35
  • HY-155760
    hCA/VEGFR-2-IN-3

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-3
  • HY-155763
    hCA/VEGFR-2-IN-4

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC50=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-4
  • HY-155758
    hCA/VEGFR-2-IN-2

    		VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC50=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-2
  • HY-162000
    hCAIX/XII-IN-13

    		Apoptosis Cancer
    hCAIX/XII-IN-13 is an inhibitor of human carbonic anhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
    hCAIX/XII-IN-13
  • HY-P1435A
    NoxA1ds TFA

    		NADPH Oxidase Cardiovascular Disease Cancer
    NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds TFA inhibits NOX1-derived O 2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .
    NoxA1ds TFA
  • HY-178475
    CA IX/GPX4-IN-1

    		Carbonic Anhydrase Glutathione Peroxidase Ferroptosis Cancer
    CA IX/GPX4-IN-1 (Compound 22abcb) is a dual targeted inhibitor of CA IX and GPX4 activity. CA IX/GPX4-IN-1 can effectively kill SUM159PT cells (IC50 = 416 nM) by inducing iron death under hypoxic conditions. CA IX/GPX4-IN-1 has an IC50 of 663 nM to CA IX in SUM159PT-CAIX-FL cells. CA IX/GPX4-IN-1 can significantly inhibit tumor growth and can be reversed by ferroptosis inhibitors. CA IX/GPX4-IN-1 can be used for research on breast cancer and other cancers .
    CA IX/GPX4-IN-1
  • HY-40136R
    cis-4-Hydroxy-L-proline (Standard)

    		Reference Standards Endogenous Metabolite Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    cis-4-Hydroxy-L-proline (Standard) is the analytical standard of cis-4-Hydroxy-L-proline (HY-40136). This product is intended for research and analytical applications. cis-4-Hydroxy-L-proline is an orally active proline analog and collagen production inhibitor. cis-4-Hydroxy-L-proline inhibits cell growth by preventing the deposition of triple helical collagen on the cell layer. cis-4-Hydroxy-L-proline inhibits N-nitrosomethylurea-induced breast tumor growth. cis-4-Hydroxy-L-proline improves lung compliance and reduces prostate weight. cis-4-Hydroxy-L-proline can be used in the study of hypoxic pulmonary hypertension .
    cis-4-Hydroxy-L-proline (Standard)
  • HY-W014394R
    Vanillyl butyl ether (Standard)

    		TRP Channel Reference Standards Parasite Cardiovascular Disease
    Protoporphyrin IX (Standard) is the analytical standard of Protoporphyrin IX. This product is intended for research and analytical applications. Protoporphyrin IX is a final intermediate in the heme biosynthetic pathway, which acts as a radiation sensitizer enhancing ROS generation even in a hypoxic state and inducing DNA damage. Protoporphyrin IX also acts as a photo sensitizer undergoing photobleaching that occurs through direct degradation by light irradiation. Protoporphyrin IX is formed and accumulated following 5-aminolevulinic acid (5-ALA) (HY-W000450) administration in the tumor cells of rats. Protoporphyrin IX causes selective improvement of basal cell carcinoma when activated red fluorescence of a peak wavelength at 405 nm. Protoporphyrin IX is promising for research of sonodynamic and photodynamic agents for a wide range of cancers, such as bladder cancer and nodular basal cell carcinoma .
    Vanillyl butyl ether (Standard)
  • HY-W778057
    Ethyl 3,4-Dihydroxybenzoate-13C3

    Protocatechuic acid ethyl ester-13C3

    		 Reactive Oxygen Species (ROS) Cancer
    Ethyl 3,4-Dihydroxybenzoate- 13C3 (Protocatechuic acid ethyl ester- 13C3) is the 13C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
    Ethyl 3,4-Dihydroxybenzoate-13C3
  • HY-W016409R
    Ethyl 3,4-dihydroxybenzoate (Standard)

    Protocatechuic acid ethyl ester (Standard)

    		 Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis Metabolic Disease Cancer
    Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .
    Ethyl 3,4-dihydroxybenzoate (Standard)
  • HY-W177315A
    5-Nitrotryptamine

    		Biochemical Assay Reagents Cancer
    5-Nitrotryptamine is a radiosensitizer. 5-Nitrotryptamine shows radiosensitizing effects. 5-Nitrotryptamine can be used in the research of hypoxic tumors .
    5-Nitrotryptamine
  • HY-105095
    Doranidazole

    PR 350; RP 343

    		 Biochemical Assay Reagents Cancer
    Doranidazole (PR 350) is a radiosensitizer. Doranidazole increases the radiosensitivity of hypoxic SCCVII cells. Doranidazole significantly enhances radiation-induced growth delay in SCCVII tumors when administered intravenously before tumor irradiation. Doranidazole radiosensitizes tumors to an extent that depends on the tumor's oxygenation status. Doranidazole can be used for the study of lymphoma and hypoxic pancreatic tumors .
    Doranidazole
  • HY-183570
    Antitumor photosensitizer-11

    		Photosensitizer Reactive Oxygen Species (ROS) Cancer
    Antitumor photosensitizer-11 is a type-I carbazole/benzindolium photosensitizer with antitumor activity. Antitumor photosensitizer-11 induces ROS generation via a type-I pathway, forming superoxide anions and hydroxyl radicals. Antitumor photosensitizer-11 triggers immunogenic cell death in cancer cells via enhanced oxidative stress. Antitumor photosensitizer-11 exhibits antiproliferative activity in normoxic and hypoxic environments, inhibits breast cancer tumor growth in vivo, and promotes dendritic cell maturation and T cell infiltration. Antitumor photosensitizer-11 can be used for the research of cancer, such as breast cancer .
    Antitumor photosensitizer-11
  • HY-116156
    SR-4554

    		Biochemical Assay Reagents Cancer
    SR-4554 is a probe for the measurement of tumor hypoxia. SR-4554 undergoes enzymatic single-electron reduction reactions within hypoxic cells. SR-4554 determines the 19F retention index for four commonly used mouse tumors (EMT6, SCCVII, KILT and RIF-I) through 19F MRS technique. SR-4554 can used to detect tumor Hypoxia noninvasively by 19F magnetic resonance spectroscopy ( 19F MRS) .
    SR-4554

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: